Multicenter evaluation of blood-based biomarkers for the detection of endometriosis and adenomyosis: A prospective non-interventional study.

Autor: Burghaus S; Department of Gynecology and Obstetrics, Erlangen University Hospital, University Endometriosis Center for Franconia, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany., Drazic P; Endometriosis Center, Ammerland Clinic GmbH, Westerstede, Germany., Wölfler M; Department of Gynecology and Obstetrics and Gynecology, Medical University, Graz, Austria., Mechsner S; Department of Gynecology, Endometriosis Research Center Charité, Charité University Hospital, Campus Virchow Klinikum, Berlin, Germany., Zeppernick M; Department of Gynecology and Obstetrics, RWTH Aachen University Hospital, Aachen, Germany.; Department of Gynecology and Obstetrics, Justus Liebig University, Giessen, Germany., Meinhold-Heerlein I; Department of Gynecology and Obstetrics, RWTH Aachen University Hospital, Aachen, Germany.; Department of Gynecology and Obstetrics, Justus Liebig University, Giessen, Germany., Mueller MD; Department of Obstetrics and Gynecology, Inselspital, University of Bern, Bern, Switzerland., Rothmund R; Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany., Vigano P; Obstetrics and Gynecology Unit, San Raffaele Scientific Institute, Milan, Italy., Becker CM; Oxford Endometriosis Care and Research (CaRe) Centre, Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, UK., Zondervan KT; Oxford Endometriosis Care and Research (CaRe) Centre, Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, UK.; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK., Beckmann MW; Department of Gynecology and Obstetrics, Erlangen University Hospital, University Endometriosis Center for Franconia, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany., Fasching PA; Department of Gynecology and Obstetrics, Erlangen University Hospital, University Endometriosis Center for Franconia, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany., Berner-Gatz S; Roche Diagnostics GmbH, Penzberg, Germany., Grünewald FS; Roche Diagnostics GmbH, Penzberg, Germany., Hund M; Roche Diagnostics International Ltd, Rotkreuz, Switzerland., Kastner P; Roche Diagnostics GmbH, Penzberg, Germany., Klammer M; Roche Diagnostics GmbH, Penzberg, Germany., Laubender RP; Roche Diagnostics GmbH, Penzberg, Germany., Wegmeyer H; Roche Diagnostics GmbH, Penzberg, Germany., Wienhues-Thelen UH; Roche Diagnostics GmbH, Penzberg, Germany., Renner SP; Department of Gynecology and Obstetrics, Erlangen University Hospital, University Endometriosis Center for Franconia, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.; Department of Gynecology and Obstetrics, Hospital Böblingen, Klinikverbund-Suedwest, Klinikum Sindelfingen-Böblingen, Böblingen, Germany.
Jazyk: angličtina
Zdroj: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics [Int J Gynaecol Obstet] 2024 Jan; Vol. 164 (1), pp. 305-314. Date of Electronic Publication: 2023 Aug 28.
DOI: 10.1002/ijgo.15062
Abstrakt: Objective: To evaluate blood-based biomarkers to detect endometriosis and/or adenomyosis across nine European centers (June 2014-April 2018).
Methods: This prospective, non-interventional study assessed the diagnostic accuracy of 54 blood-based biomarker immunoassays in samples from 919 women (aged 18-45 years) with suspicion of endometriosis and/or adenomyosis versus symptomatic controls. Endometriosis was stratified by revised American Society for Reproductive Medicine stage. Symptomatic controls were "pathologic symptomatic controls" or "pathology-free symptomatic controls". The main outcome measure was receiver operating characteristic-area under the curve (ROC-AUC) and Wilcoxon P values corrected for multiple testing (q values).
Results: CA-125 performed best in "all endometriosis cases" versus "all symptomatic controls" (AUC 0.645, 95% confidence interval [CI] 0.600-0.690, q < 0.001) and increased (P < 0.001) with disease stage. In "all endometriosis cases" versus "pathology-free symptomatic controls", S100-A12 performed best (AUC 0.692, 95% CI 0.614-0.769, q = 0.001) followed by CA-125 (AUC 0.649, 95% CI 0.569-0.729, q = 0.021). In "adenomyosis only cases" versus "symptomatic controls" or "pathology-free symptomatic controls", respectively, the top-performing biomarkers were sFRP-4 (AUC 0.615, 95% CI 0.551-0.678, q = 0.045) and S100-A12 (AUC 0.701, 95% CI 0.611-0.792, q = 0.004).
Conclusion: This study concluded that no biomarkers tested could diagnose or rule out endometriosis/adenomyosis with high certainty.
(© 2023 The Authors. International Journal of Gynecology & Obstetrics published by John Wiley & Sons Ltd on behalf of International Federation of Gynecology and Obstetrics.)
Databáze: MEDLINE
Externí odkaz: